Related Experiment Video
Updated: May 19, 2026
08:00
Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis
Published on: May 26, 2021
Does selective beta-1 blockade provide bone marrow protection after trauma/hemorrhagic shock?
Latha V Pasupuleti1, Kristin M Cook, Ziad C Sifri
1Division of Trauma, Department of Surgery, UMDNJ-New Jersey Medical School, Newark, NJ, USA.
Surgery
|September 4, 2012
Summary
Selective beta-2 and beta-3 blockers protect bone marrow (BM) after trauma and hemorrhagic shock (HS). Beta-1 blockers were ineffective, indicating protection is not cardiovascular.
Area of Science:
- Pharmacology
- Trauma Research
- Hematology
Background:
- Nonselective beta-blockade (BB) previously showed bone marrow (BM) protection after trauma and hemorrhagic shock (HS).
- Selective beta-1 blockers are common for cardiac protection, necessitating investigation into specific beta-adrenergic receptor roles in BM protection.
Purpose of the Study:
- To define the role of specific beta-adrenergic receptors in bone marrow (BM) protection following trauma and hemorrhagic shock (HS).
Main Methods:
- Male Sprague-Dawley rats underwent lung contusion (LC) and HS.
- Animals received selective beta-1, beta-2, or beta-3 blockers post-resuscitation.
- Bone marrow cellularity, hematopoietic progenitor cell (HPC) growth, and hemoglobin (Hb) levels were assessed at 3 hours and 7 days.
Main Results:
- Selective beta-2 and beta-3 blockers restored BM cellularity and HPC growth at both time points.
- Beta-1 blocker treatment had no effect on BM cellularity or HPC growth.
- Beta-3 blocker treatment increased hemoglobin levels compared to HS alone.
Conclusions:
- Selective beta-2 and beta-3 blockers provide significant bone marrow (BM) protection for up to 7 days after trauma and hemorrhagic shock (HS).
- Beta-1 blockers do not protect the BM, despite reducing heart rate.
- BM protection is mediated by beta-2 and beta-3 receptors, independent of direct cardiovascular effects.
Related Concept Videos
01:28Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
01:17Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:22Bone Marrow Sampling and Transplants
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...